Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stryker Buys Target Neurovascular Biz From Boston Scientific For $1.5 Billion

This article was originally published in The Gray Sheet

Executive Summary

Stryker will enter the neurovascular market and become segment leader through the $1.5 billion purchase of Target Therapeutics from Boston Scientific, the firms announced Oct. 28.

You may also be interested in...

Stryker M&A Strategy Intact Under New CEO With Latest Deal For Stroke Care

Purchase of Surpass Medical for $135 million represents Stryker’s 10th acquisition since 2009. The company affirmed its acquisition strategy focused on core and key adjacent markets during its Oct. 17 earnings call, but also sought to ratchet down earnings growth expectations in the near term to account for headwinds, including the upcoming U.S. medical device excise tax.

FDA Narrows Indication For Stryker’s Wingspan Intracranial Stent

Agency restricts use of the device to a select patient population with severe intracranial stenosis and recurrent stroke after reviewing studies indicating the device could actually lead to increased rates of stroke and death.

Most Companies Still Mum On Device Tax Coping Strategies

While some companies have started to reveal strategies to either soften the blow or to capitalize on the impending device excise tax, many have revealed little to no detail on their planned response.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts